Prostate cancer trials recruiting in Utah

All Prostate cancer trials nationally

Cities in Utah

Recruiting trials in Utah

• A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC
  NCT07226986 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Male · Utah: Murray
• A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
  NCT07503808 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Utah: West Valley City
• A Study of JNJ-98768111 in Participants With Advanced Prostate Cancer
  NCT07746713 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male · Utah: West Valley City
• A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
  NCT06465069 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Utah: Salt Lake City, West Valley City
• A Study of MGC026 in Participants With Advanced Solid Tumors
  NCT06242470 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Utah: West Valley City
• A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
  NCT06952803 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · Utah: Salt Lake City
• A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
  NCT06395519 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Utah: Salt Lake City
• A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
  NCT07164443 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · Utah: Salt Lake City
• A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer
  NCT06533644 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · Utah: Murray
• A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
  NCT06764485 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · Utah: Murray
• A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors
  NCT07540572 · Phase: Phase 1 · Ages: 18 Years to 99 Years · Sex: All (male and female) · Utah: West Valley City
• A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)
  NCT07723248 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · Utah: Murray
• A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs
  NCT07336446 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Male · Utah: Salt Lake City
• AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
  NCT07611110 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · Utah: Salt Lake City
• Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer
  NCT05168618 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · Utah: Salt Lake City
• Creatine Supplementation and Resistance Training to Preserve Muscle Mass and Attenuate Cancer Progression
  NCT06112990 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · Utah: Salt Lake City
• Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
  NCT06592924 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · Utah: Salt Lake City
• Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
  NCT07517198 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Utah: West Valley City
• Dose-Escalation Study of Cabozantinib in Combination With Lutetium-177 (177Lu)-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer
  NCT05613894 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male · Utah: Salt Lake City
• First-Time-in-Human Study of GSK5471713 in Adults With mCRPC
  NCT07332455 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Male · Utah: West Valley City
• Impact of Multimodal Telerehabilitation in Rural Patients With Metastatic Prostate Cancer
  NCT07032584 · Phase: Not applicable (e.g. observational or device study) · Ages: 21 Years and older · Sex: Male · Utah: Salt Lake City
• Multimodal Telerehabilitation of Rural Patients With Advanced Prostate Cancer
  NCT07093177 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: Male · Utah: Salt Lake City
• Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
  NCT06780670 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 100 Years · Sex: Male · Utah: Murray
• Optimal PSA Triggered Individual Management of Androgen Sensitive Prostate Cancer
  NCT07216248 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · Utah: Salt Lake City
• Pembro With Radiation With or Without Olaparib
  NCT05568550 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · Utah: Salt Lake City
• Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors
  NCT06784193 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Utah: West Valley City
• Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors
  NCT07145255 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Utah: West Valley City
• Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
  NCT06056830 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · Utah: Murray
• SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
  NCT03452774 · Phase: Not specified · Ages: No age limits stated · Sex: All (male and female) · Utah: Salt Lake City
• Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
  NCT03678025 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · Utah: American Fork, Cedar City, Logan, Murray
• Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
  NCT04221542 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male · Utah: Murray
• Study of Apalutamide With Carotuximab in Metastatic, Castration-Resistant Prostate Cancer
  NCT05534646 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · Utah: Salt Lake City
• Study of ORIC-944 in Patients With Metastatic Prostate Cancer
  NCT05413421 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male · Utah: Salt Lake City
• Study of Oral MRT-2359 With Apalutamide in Prostate Cancer
  NCT07745361 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · Utah: West Valley City
• Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
  NCT05946213 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · Utah: American Fork, Cedar City, Farmington, Logan
• Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
  NCT06931340 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · Utah: Murray, Ogden, Salt Lake City, St. George
• The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)
  NCT06520345 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · Utah: Murray, Salt Lake City
• This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
  NCT07028853 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · Utah: Salt Lake City
• TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
  NCT07190300 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Male · Utah: Salt Lake City
• XL092 in Patients With Metastatic Castration-Resistant Prostate Cancer
  NCT06568562 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · Utah: Salt Lake City